Patrick Cheung1, Samir Patel2, Scott A North3, Arjun Sahgal1, William Chu1, Hany Soliman1, Belal Ahmad4, Eric Winquist5, Tamim Niazi6, Francois Patenaude7, Gerald Lim8, Daniel Yick Chin Heng9, Arbind Dubey10, Piotr Czaykowski11, Rebecca K S Wong12, Anand Swaminath13, Scott C Morgan14, Rupi Mangat15, Sareh Keshavarzi16, Georg A Bjarnason17. 1. Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. 2. Division of Radiation Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. 3. Division of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada. 4. Division of Radiation Oncology, Department of Oncology, London Health Sciences Centre, Western University, London, ON, Canada. 5. Division of Medical Oncology, Department of Oncology, London Health Sciences Centre, Western University, London, ON, Canada. 6. Division of Radiation Oncology, Department of Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada. 7. Department of Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada. 8. Division of Radiation Oncology, Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. 9. Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. 10. Department of Radiation Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada. 11. Department of Medical Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada. 12. Radiation Medicine Program, Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. 13. Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada. 14. Division of Radiation Oncology, Department of Radiology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada. 15. Ozmosis Research Inc., Toronto, ON, Canada. 16. Department of Biostatistics, Princess Margaret Cancer Centre, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. 17. Division of Medical Oncology, Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada. Electronic address: georg.bjarnason@sunnybrook.ca.
Abstract
BACKGROUND: Despite the paucity of prospective evidence, stereotactic radiotherapy (SRT) is increasingly being considered in the setting of oligoprogression to delay the need to change systemic therapy. OBJECTIVE: To determine the local control (LC), progression-free survival (PFS), cumulative incidence of changing systemic therapy, and overall survival (OS) after SRT to oligoprogressive metastatic renal cell carcinoma (mRCC) lesions in patients who are on tyrosine kinase inhibitor (TKI) therapy. DESIGN, SETTING, AND PARTICIPANTS: A prospective multicenter study was performed to evaluate the use of SRT in oligoprogressive mRCC patients. Patients with mRCC who had previous stability or response after ≥3 mo of TKI therapy were eligible if they developed progression of five of fewer metastases. Thirty-seven patients with 57 oligoprogressive tumors were enrolled. INTERVENTION: Oligoprogressive tumors were treated with SRT, and the same TKI therapy was continued afterward. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Competing risk analyses and the Kaplan-Meir methodology were used to report the outcomes of interest. RESULTS AND LIMITATIONS: The median duration of TKI therapy prior to study entry was 18.6 mo; 1-yr LC of the irradiated tumors was 93% (95% confidence interval [CI] 71-98%). The median PFS after SRT was 9.3 mo (95% CI 7.5-15.7 mo). The cumulative incidence of changing systemic therapy was 47% (95% CI 32-68%) at 1 yr, with a median time to change in systemic therapy of 12.6 mo (95% CI 9.6-17.4 mo). One-year OS was 92% (95% CI 82-100%). There were no grade 3-5 SRT-related toxicities. CONCLUSIONS: LC of irradiated oligoprogressive mRCC tumors was high, and the need to change systemic therapy was delayed for a median of >1 yr. PATIENT SUMMARY: The use of stereotactic radiotherapy in metastatic kidney cancer patients, who develop growth of a few tumors while on oral targeted therapy, can significantly delay the need to change to the next line of drug therapy.
BACKGROUND: Despite the paucity of prospective evidence, stereotactic radiotherapy (SRT) is increasingly being considered in the setting of oligoprogression to delay the need to change systemic therapy. OBJECTIVE: To determine the local control (LC), progression-free survival (PFS), cumulative incidence of changing systemic therapy, and overall survival (OS) after SRT to oligoprogressive metastatic renal cell carcinoma (mRCC) lesions in patients who are on tyrosine kinase inhibitor (TKI) therapy. DESIGN, SETTING, AND PARTICIPANTS: A prospective multicenter study was performed to evaluate the use of SRT in oligoprogressive mRCC patients. Patients with mRCC who had previous stability or response after ≥3 mo of TKI therapy were eligible if they developed progression of five of fewer metastases. Thirty-seven patients with 57 oligoprogressive tumors were enrolled. INTERVENTION: Oligoprogressive tumors were treated with SRT, and the same TKI therapy was continued afterward. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Competing risk analyses and the Kaplan-Meir methodology were used to report the outcomes of interest. RESULTS AND LIMITATIONS: The median duration of TKI therapy prior to study entry was 18.6 mo; 1-yr LC of the irradiated tumors was 93% (95% confidence interval [CI] 71-98%). The median PFS after SRT was 9.3 mo (95% CI 7.5-15.7 mo). The cumulative incidence of changing systemic therapy was 47% (95% CI 32-68%) at 1 yr, with a median time to change in systemic therapy of 12.6 mo (95% CI 9.6-17.4 mo). One-year OS was 92% (95% CI 82-100%). There were no grade 3-5 SRT-related toxicities. CONCLUSIONS: LC of irradiated oligoprogressive mRCC tumors was high, and the need to change systemic therapy was delayed for a median of >1 yr. PATIENT SUMMARY: The use of stereotactic radiotherapy in metastatic kidney cancer patients, who develop growth of a few tumors while on oral targeted therapy, can significantly delay the need to change to the next line of drug therapy.
Authors: Rohan R Katipally; Sean P Pitroda; Aditya Juloori; Steven J Chmura; Ralph R Weichselbaum Journal: Nat Rev Clin Oncol Date: 2022-07-12 Impact factor: 65.011
Authors: Eric K Nguyen; Aly Khan A Lalani; Sunita Ghosh; Naveen S Basappa; Anil Kapoor; Aaron R Hansen; Christian Kollmannsberger; Daniel Heng; Lori A Wood; Vincent Castonguay; Denis Soulières; Eric Winquist; Christina Canil; Jeffrey Graham; Georg A Bjarnason; Rodney H Breau; Frédéric Pouliot; Anand Swaminath Journal: Adv Radiat Oncol Date: 2022-01-16
Authors: Anil Kapoor; Tamim Niazi; Krista Noonan; Ricardo A Rendon; Nimira Alimohamed; Wassim Kassouf; Alejandro Berlin; William Chu; Christian Kollmannsberger; Alan I So Journal: Can Urol Assoc J Date: 2022-04 Impact factor: 2.052
Authors: Raquibul Hannan; Michael Christensen; Hans Hammers; Alana Christie; Brendan Paulman; Dandan Lin; Aurelie Garant; Waddah Arafat; Kevin Courtney; Isaac Bowman; Suzanne Cole; David Sher; Chul Ahn; Hak Choy; Robert Timmerman; James Brugarolas Journal: Eur Urol Oncol Date: 2022-01-02